Symbols / MBX Stock $31.96 -4.28% MBX Biosciences, Inc.

Healthcare • Biotechnology • United States • NMS
MBX (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Biotechnology
CEO Mr. Peter Kent Hawryluk MBA
Exch · Country NMS · United States
Market Cap 1.52B
Enterprise Value 1.15B
Income -86.97M
Sales —
FCF (ttm) -52.44M
Book/sh 8.22
Cash/sh 7.87
Employees 63
Insider 10d —
IPO Sep 13, 2024
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E —
Forward P/E -7.80
PEG —
P/S —
P/B 3.89
P/C —
EV/EBITDA -11.71
EV/Sales —
Quick Ratio 24.25
Current Ratio 24.62
Debt/Eq 0.16
LT Debt/Eq —
EPS (ttm) -2.38
EPS next Y -4.10
EPS Growth —
Revenue Growth —
EPS Gr Q/Q —
Rev Gr Q/Q —
Earnings (next) 2026-05-11
Earnings (prior) 2026-03-12
ROA -18.75%
ROE -27.76%
ROIC —
Gross Margin 0.00%
Oper. Margin 0.00%
Profit Margin 0.00%
Shs Outstand 47.57M
Shs Float 29.03M
Insider Own 2.68%
Instit Own 104.75%
Short Float 11.17%
Short Ratio 7.97
Short Interest 3.79M
52W High 44.89
vs 52W High -28.80%
52W Low 8.99
vs 52W Low 255.31%
Beta —
Impl. Vol. 48.40%
Rel Volume 0.82
Avg Volume 549.12K
Volume 448.14K
Target (mean) $62.55
Tgt Median $66.00
Tgt Low $20.00
Tgt High $88.00
# Analysts 11
Recom Strong_buy
Prev Close $33.39
Price $31.96
Change -4.28%
About

MBX Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders. Its lead product candidate is Canvuparatide (MBX 2109), a parathyroid hormone peptide prodrug, which is in Phase 3 clinical trial for the treatment of chronic hypoparathyroidism. The company is also developing Imapextide (MBX 1416), a long-acting glucagon-like peptide-1 (GLP-1) receptor antagonist that is in Phase 2 clinical trial a potential therapy for post-bariatric hypoglycemia, a chronic complication of bariatric surgery. In addition, it is developing MBX 4291, a lead obesity product candidate, which is in investigational new drug-enabling studies for the treatment of obesity and co-morbidities. The company was founded in 2018 and is based in Carmel, Indiana.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$62.55
Mean price target
2. Current target
$31.96
Latest analyst target
3. DCF / Fair value
$-19.84
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$31.96
Low
$20.00
High
$88.00
Mean
$62.55

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2026-01-28 init Barclays — → Overweight $66
2026-01-16 main Guggenheim Buy → Buy $88
2026-01-07 init UBS — → Buy $60
2025-12-19 main Stifel Buy → Buy $50
2025-12-04 init Goldman Sachs — → Sell $18
2025-11-10 main Guggenheim Buy → Buy $77
2025-11-04 init TD Cowen — → Buy —
2025-10-15 init Truist Securities — → Buy $50
2025-09-24 main Mizuho Outperform → Outperform $56
2025-09-23 main Oppenheimer Outperform → Outperform $80
2025-09-23 main Guggenheim Buy → Buy $84
2025-08-05 init Mizuho — → Outperform $38
2025-07-16 init Oppenheimer — → Outperform $38
2025-04-10 init JMP Securities — → Market Outperform $38
2025-04-10 reit Guggenheim Buy → Buy $44
2024-10-08 init Jefferies — → Buy $35
2024-10-08 init JP Morgan — → Overweight $30
2024-10-08 init Stifel — → Buy $40
2024-10-08 init Guggenheim — → Buy $44
News
RSS: Latest MBX news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2026-03-13 HAWRYLUK P KENT Chief Executive Officer — 18,500 $28.41 $525,663
2026-02-26 HAWRYLUK P KENT Chief Executive Officer — 28,768 $16.00 $460,288
2026-02-02 HAWRYLUK P KENT Chief Executive Officer — 35,250 $0.00 $0
2026-02-02 BARTRAM RICHARD B Chief Financial Officer — 15,000 $0.00 $0
2026-02-02 AZOULAY SALOMON M.D. Officer — 15,000 $0.00 $0
2025-10-24 HAWRYLUK P KENT Chief Executive Officer — 182,859 $3.25 $594,292
2025-10-20 HAWRYLUK P KENT Chief Executive Officer — 20,000 $13.64 $272,790
2025-10-17 HOERTER STEVEN L Director — 20,000 $13.25 $264,984
2025-09-26 HERON PATRICK J Director and Beneficial Owner of more than 10% of a Class of Security — 666,666 $18.00 $11,999,988
2025-04-08 PESCOVITZ ORA H Director — 7,693 $5.89 $45,312
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
0.00
0.00
0.00
0.00
Operating Revenue
0.00
0.00
0.00
0.00
Operating Expense
98.06
+43.79%
68.19
+93.12%
35.31
+40.34%
25.16
Research And Development
79.16
+37.87%
57.41
+101.22%
28.53
+33.36%
21.40
Selling General And Administration
18.90
+75.30%
10.78
+59.05%
6.78
+80.05%
3.76
General And Administrative Expense
18.90
+75.30%
10.78
+59.05%
6.78
+80.05%
3.76
Other Gand A
18.90
+75.30%
10.78
+59.05%
6.78
+80.05%
3.76
Total Expenses
98.06
+43.79%
68.19
+93.12%
35.31
+40.34%
25.16
Operating Income
-98.06
-43.79%
-68.19
-93.12%
-35.31
-40.34%
-25.16
Total Operating Income As Reported
-98.06
-43.79%
-68.19
-93.12%
-35.31
-40.34%
-25.16
EBITDA
-97.81
-43.94%
-67.95
-93.29%
-35.15
-36.76%
-25.70
Normalized EBITDA
-97.81
-43.94%
-67.95
-93.29%
-35.15
-42.13%
-24.73
Reconciled Depreciation
0.25
+1.64%
0.24
+55.41%
0.16
+180.36%
0.06
EBIT
-98.06
-43.79%
-68.19
-93.12%
-35.31
-37.07%
-25.76
Total Unusual Items
—
—
0.00
+100.00%
-0.97
Total Unusual Items Excluding Goodwill
—
—
0.00
+100.00%
-0.97
Special Income Charges
—
—
0.00
+100.00%
-0.90
Other Special Charges
—
—
—
0.90
Net Income
-86.97
-40.45%
-61.92
-90.16%
-32.56
-24.60%
-26.14
Pretax Income
-86.97
-40.45%
-61.92
-90.16%
-32.56
-24.60%
-26.14
Net Non Operating Interest Income Expense
11.08
+76.72%
6.27
+128.24%
2.75
+137500.00%
-0.00
Interest Expense Non Operating
—
—
0.00
-100.00%
0.37
Net Interest Income
11.08
+76.72%
6.27
+128.24%
2.75
+137500.00%
-0.00
Interest Expense
—
—
0.00
-100.00%
0.37
Interest Income Non Operating
11.08
+76.72%
6.27
+128.24%
2.75
+638.71%
0.37
Interest Income
11.08
+76.72%
6.27
+128.24%
2.75
+638.71%
0.37
Other Income Expense
—
—
—
-0.97
Gain On Sale Of Security
—
—
—
-0.07
Tax Rate For Calcs
0.00
0.00
0.00
0.00
Tax Effect Of Unusual Items
0.00
0.00
0.00
0.00
Net Income Including Noncontrolling Interests
-86.97
-40.45%
-61.92
-90.16%
-32.56
-24.60%
-26.14
Net Income From Continuing Operation Net Minority Interest
-86.97
-40.45%
-61.92
-90.16%
-32.56
-24.60%
-26.14
Net Income From Continuing And Discontinued Operation
-86.97
-40.45%
-61.92
-90.16%
-32.56
-24.60%
-26.14
Net Income Continuous Operations
-86.97
-40.45%
-61.92
-90.16%
-32.56
-24.60%
-26.14
Normalized Income
-86.97
-40.45%
-61.92
-90.16%
-32.56
-29.41%
-25.16
Net Income Common Stockholders
-86.97
-40.45%
-61.92
-90.16%
-32.56
-24.60%
-26.14
Diluted EPS
—
-5.82
-469.32%
-1.02
-24.60%
-0.82
Basic EPS
—
-5.82
-469.32%
-1.02
-24.60%
-0.82
Basic Average Shares
—
10.64
-66.59%
31.85
+0.00%
31.85
Diluted Average Shares
—
10.64
-66.59%
31.85
+0.00%
31.85
Diluted NI Availto Com Stockholders
-86.97
-40.45%
-61.92
-90.16%
-32.56
-24.60%
-26.14
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Assets
385.14
+43.42%
268.54
+219.00%
84.18
+86.67%
45.09
Current Assets
381.54
+42.75%
267.29
+220.24%
83.47
+88.79%
44.21
Cash Cash Equivalents And Short Term Investments
373.70
+42.55%
262.15
+224.94%
80.68
+90.00%
42.46
Cash And Cash Equivalents
75.29
+52.56%
49.35
+61.68%
30.52
+26.08%
24.21
Other Short Term Investments
298.42
+40.23%
212.80
+324.30%
50.15
+174.80%
18.25
Receivables
2.12
+210.85%
0.68
+227.88%
0.21
+46.48%
0.14
Accrued Interest Receivable
2.12
+210.85%
0.68
+227.88%
0.21
+46.48%
0.14
Prepaid Assets
4.85
+32.89%
3.65
+49.18%
2.45
+60.63%
1.52
Other Current Assets
0.86
+7.22%
0.80
+503.76%
0.13
+58.33%
0.08
Total Non Current Assets
3.60
+188.63%
1.25
+74.69%
0.71
-19.12%
0.88
Net PPE
3.22
+168.72%
1.20
+80.30%
0.67
-21.02%
0.84
Gross PPE
3.89
+140.10%
1.62
+92.29%
0.84
-6.12%
0.90
Accumulated Depreciation
-0.67
-58.77%
-0.42
-137.08%
-0.18
-217.86%
-0.06
Properties
0.00
0.00
0.00
0.00
Machinery Furniture Equipment
0.38
+30.17%
0.29
+33.48%
0.22
+7.28%
0.21
Construction In Progress
1.62
0.00
-100.00%
0.00
0.00
Other Properties
1.37
+46.74%
0.94
+278.54%
0.25
-27.78%
0.34
Leases
0.52
+32.99%
0.39
+5.11%
0.37
+6.29%
0.35
Non Current Deferred Assets
0.34
0.00
—
—
Non Current Prepaid Assets
0.04
-16.00%
0.05
+0.00%
0.05
—
Other Non Current Assets
—
—
0.05
+19.05%
0.04
Total Liabilities Net Minority Interest
15.92
+43.52%
11.09
-92.92%
156.65
+78.62%
87.70
Current Liabilities
15.49
+40.21%
11.05
+181.48%
3.93
+14.43%
3.43
Payables And Accrued Expenses
11.00
+28.59%
8.56
+255.32%
2.41
+11.43%
2.16
Payables
2.98
-44.20%
5.33
+283.54%
1.39
+42.52%
0.98
Accounts Payable
2.98
-44.20%
5.33
+283.54%
1.39
+42.52%
0.98
Current Accrued Expenses
8.03
+149.15%
3.22
+216.72%
1.02
-14.18%
1.19
Pensionand Other Post Retirement Benefit Plans Current
4.32
+85.93%
2.32
+70.26%
1.36
+20.48%
1.13
Current Debt And Capital Lease Obligation
0.17
+0.58%
0.17
+11.76%
0.15
+11.68%
0.14
Current Capital Lease Obligation
0.17
+0.58%
0.17
+11.76%
0.15
+11.68%
0.14
Total Non Current Liabilities Net Minority Interest
0.43
+914.29%
0.04
-99.97%
152.72
+81.23%
84.27
Long Term Debt And Capital Lease Obligation
0.42
0.00
-100.00%
0.17
-47.22%
0.32
Long Term Capital Lease Obligation
0.42
0.00
-100.00%
0.17
-47.22%
0.32
Other Non Current Liabilities
0.00
-95.24%
0.04
-78.35%
0.19
+193.94%
0.07
Preferred Securities Outside Stock Equity
—
0.00
-100.00%
152.36
+81.64%
83.88
Stockholders Equity
369.22
+43.42%
257.44
+455.25%
-72.47
-70.09%
-42.60
Common Stock Equity
369.22
+43.42%
257.44
+455.25%
-72.47
-70.09%
-42.60
Capital Stock
0.01
+20.00%
0.01
+400.00%
0.00
+0.00%
0.00
Common Stock
0.01
+20.00%
0.01
+400.00%
0.00
+0.00%
0.00
Preferred Stock
0.00
0.00
0.00
—
Share Issued
44.93
+34.43%
33.42
+4.92%
31.85
+0.00%
31.85
Ordinary Shares Number
44.93
+34.43%
33.42
+4.92%
31.85
+0.00%
31.85
Additional Paid In Capital
593.41
+50.27%
394.89
+12830.16%
3.05
+643.07%
0.41
Retained Earnings
-224.48
-63.25%
-137.50
-81.93%
-75.58
-75.69%
-43.02
Gains Losses Not Affecting Retained Earnings
0.29
+420.00%
0.06
-8.33%
0.06
+1900.00%
0.00
Other Equity Adjustments
0.29
+420.00%
0.06
-8.33%
0.06
+1900.00%
0.00
Total Equity Gross Minority Interest
369.22
+43.42%
257.44
+455.25%
-72.47
-70.09%
-42.60
Total Capitalization
369.22
+43.42%
257.44
+455.25%
-72.47
-70.09%
-42.60
Working Capital
366.04
+42.85%
256.24
+222.15%
79.54
+95.04%
40.78
Invested Capital
369.22
+43.42%
257.44
+455.25%
-72.47
-70.09%
-42.60
Total Debt
0.60
+248.54%
0.17
-47.22%
0.32
-29.72%
0.46
Capital Lease Obligations
0.60
+248.54%
0.17
-47.22%
0.32
-29.72%
0.46
Net Tangible Assets
369.22
+43.42%
257.44
+455.25%
-72.47
-70.09%
-42.60
Tangible Book Value
369.22
+43.42%
257.44
+455.25%
-72.47
-70.09%
-42.60
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
-79.95
-46.21%
-54.68
-71.00%
-31.98
-38.30%
-23.12
Cash Flow From Continuing Operating Activities
-79.95
-46.21%
-54.68
-71.00%
-31.98
-38.30%
-23.12
Net Income From Continuing Operations
-86.97
-40.45%
-61.92
-90.16%
-32.56
-24.60%
-26.14
Depreciation Amortization Depletion
0.25
+1.64%
0.24
+55.41%
0.16
+180.36%
0.06
Depreciation
0.25
+1.64%
0.24
+55.41%
0.16
+180.36%
0.06
Depreciation And Amortization
0.25
+1.64%
0.24
+55.41%
0.16
+180.36%
0.06
Other Non Cash Items
0.13
+25.47%
0.11
+11.58%
0.10
-77.16%
0.42
Stock Based Compensation
8.68
+66.16%
5.22
+155.60%
2.04
+567.65%
0.31
Operating Gains Losses
—
—
0.07
-92.90%
0.97
Gain Loss On Investment Securities
—
—
—
0.07
Gain Loss On Sale Of PPE
—
0.00
-100.00%
0.07
0.00
Change In Working Capital
1.57
-65.74%
4.60
+725.44%
-0.73
-156.98%
1.29
Change In Prepaid Assets
-2.70
-14.86%
-2.35
-124.26%
-1.05
-32.36%
-0.79
Change In Payables And Accrued Expense
4.34
-38.86%
7.10
+1453.17%
0.46
-78.47%
2.12
Change In Accrued Expense
6.80
+114.32%
3.17
+6946.67%
0.04
-96.90%
1.45
Change In Payable
-2.46
-162.54%
3.93
+853.16%
0.41
-38.60%
0.67
Change In Account Payable
-2.46
-162.54%
3.93
+853.16%
0.41
-38.60%
0.67
Change In Other Current Assets
-0.49
0.00
+100.00%
-0.01
+80.95%
-0.04
Change In Other Current Liabilities
0.42
+377.78%
-0.15
-11.68%
-0.14
0.00
Investing Cash Flow
-83.70
+47.88%
-160.59
-419.27%
-30.93
-171.03%
-11.41
Cash Flow From Continuing Investing Activities
-83.70
+47.88%
-160.59
-419.27%
-30.93
-171.03%
-11.41
Net PPE Purchase And Sale
-1.93
-120.71%
-0.87
-577.52%
-0.13
+70.75%
-0.44
Purchase Of PPE
-1.93
-120.71%
-0.87
-577.52%
-0.13
+70.75%
-0.44
Capital Expenditure
-1.93
-120.71%
-0.87
-577.52%
-0.13
+70.75%
-0.44
Net Investment Purchase And Sale
-81.78
+48.80%
-159.72
-418.61%
-30.80
-180.75%
-10.97
Purchase Of Investment
-358.15
-49.56%
-239.47
-275.36%
-63.80
-215.52%
-20.22
Sale Of Investment
276.37
+246.55%
79.75
+141.67%
33.00
+256.76%
9.25
Financing Cash Flow
189.59
-19.01%
234.10
+238.21%
69.22
+50.27%
46.06
Cash Flow From Continuing Financing Activities
189.59
-19.01%
234.10
+238.21%
69.22
+50.27%
46.06
Net Issuance Payments Of Debt
—
—
0.00
-100.00%
10.00
Issuance Of Debt
—
—
0.00
-100.00%
10.00
Long Term Debt Issuance
—
—
0.00
-100.00%
10.00
Net Long Term Debt Issuance
—
—
0.00
-100.00%
10.00
Net Common Stock Issuance
187.95
+7.68%
174.54
0.00
—
Proceeds From Stock Option Exercised
2.42
+499.26%
0.40
-45.47%
0.74
+2363.33%
0.03
Net Other Financing Charges
-0.77
+82.24%
-4.34
-14370.00%
-0.03
+93.45%
-0.46
Changes In Cash
25.94
+37.76%
18.83
+198.24%
6.31
-45.25%
11.53
Beginning Cash Position
49.35
+61.68%
30.52
+26.08%
24.21
+90.93%
12.68
End Cash Position
75.29
+52.56%
49.35
+61.68%
30.52
+26.08%
24.21
Free Cash Flow
-81.88
-47.38%
-55.55
-73.03%
-32.11
-36.26%
-23.56
Amortization Of Securities
-3.61
-23.33%
-2.93
-180.46%
-1.04
-3766.67%
-0.03
Common Stock Issuance
187.95
+7.68%
174.54
0.00
—
Issuance Of Capital Stock
187.95
-21.04%
238.04
+247.46%
68.51
+87.74%
36.49
Net Preferred Stock Issuance
0.00
-100.00%
63.50
-7.31%
68.51
+87.74%
36.49
Preferred Stock Issuance
0.00
-100.00%
63.50
-7.31%
68.51
+87.74%
36.49
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category